Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The Fraud of Biological Psychiatry -- Ignore unavailable to you. Want to Upgrade?

To: Don Pueblo who wrote (275)	9/11/2001 12:56:35 AM
From: Intrepid1	Respond to of 444

My buddy has an ill tempered dog which was recently prescribed doggie prozac. I hope this doesn't cause him to gun down the postman. (the doggie prozac part is true) bergen.com etc.

To: Don Pueblo who wrote (275)	9/26/2001 11:20:08 AM
From: Level Head	Read Replies (1) \| Respond to of 444

Dear Tastes Like Chicken, This was posted to a list dealing with issues of evolution science versus creation mythology. I thought that you would find it interesting and appropriate to this list. It is actually somewhat comforting to me... {g} Level Head ------------------------------------------------------------------------------------------- Subject: Physiological difference in brain function of higher IQ Finally, the higher one goes on the I.Q. scale, the greater the percentage of ADD one finds. From an I.Q. of about 160 and above, virtually everyone has ADD. Now, if that is "brain damage," as was previously felt, we should all be so damaged! Certainly it is not brain damage, and the sooner we acknowledge this, the sooner we will be able to take a more appropriate approach to ADD. Dr. Paul Elliot -------------------------------------------------------------------------------------------

To: Don Pueblo who wrote (275)	10/4/2001 3:31:57 AM
From: EL KABONG!!!	Read Replies (1) \| Respond to of 444

Knowing how you feel regarding certain drugs, I thought this article might interest you... thestreet.com Plunging Prozac Sales Dim Lilly's Outlook By Adam Feuerstein Staff Reporter 10/03/2001 09:28 AM EDT Slumping Prozac sales are depressing Eli Lilly's (LLY:NYSE - news - commentary - research) profits. The drugmaker warned Wednesday of lower fourth-quarter and year-end profits due to a severe erosion in sales of Prozac. Generic versions of the antidepressant drug hit the market in August. The company is also taking down 2002 earnings estimates because of increased investment in new drugs that should begin bolstering Lilly's bottom line in 2003. Shares of Lilly fell $2.87 to $80 per share on Instinet preopen trading Wednesday. Lilly reiterated third-quarter earnings of 66 cents per share, which matches reduced Wall Street expectations. But fourth-quarter earnings will be in the range of 59 cents per share to 61 cents per share. Analysts were looking for earnings of 65 cents per share, according to Thomson Financial/First Call. "With nearly two months of Prozac sales data available, the erosion in prescriptions is the most severe ever for a blockbuster product in our industry. This affects our financial expectations for 2001 and 2002, with a particular impact in the fourth quarter of this year," said Sidney Taurel, Lilly's chairman, president and chief executive officer. In August, Lilly lost patent protection on Prozac, its top seller, which contributed $2.5 billion in global sales in 2000. By September, prescription data revealed that less-expensive generic versions of the drug had grabbed 80% of Prozac's market share. Lilly said Wednesday that it now expects full-year 2001 earnings of $2.75 per share to $2.77 per share, resulting in single-digit earnings-per-share growth for 2001. This is lower than previous 2001 earnings guidance of $2.76 per share to $2.84 per share. Lilly is basically writing off this year and next in anticipation of rebounding sales and earnings growth starting in 2003. For 2002, the drug maker now forecasts earnings in the range of $2.70 per share to $2.80 per share. Wall Street was looking for earnings of $2.94 per share. The reduced earnings are a result of additional investment required to bring new drugs in the pipeline to market, the company said. In 2003, Lilly expects to replace Prozac sales -- and build earnings per share growth back to the high-teens -- through sales of five new product launches, including the sepsis drug Xigris, the osteoporosis drug Forteo and the erectile dysfunction drug Cialis. Lilly said Wednesday that the Food and Drug Administration has sent an "approvable letter" to the company regarding Forteo. Several issues, including the drug's labeling and manufacturing, need to be cleared up before the drug receives final approval. Xigris will be discussed at an FDA advisory panel on Oct. 16, while Cialis' approval application was sent to the FDA in late June. KJC